Search
EHA Statement on the Erasmus MC Attack
EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.
Read morePractical information
Timelines:Application deadline: August 30, 2024 (15:00 CEST)
Notification of awards: December 2024
When & where do the meetings take place?Workshop 1:
Date: April 22-26, 2025
Venue: Cambridge, UK
CBTH session and EHA Congress:
Date: June 11-15, 2025
Venue: TBC
Workshop 2:
Date:…
EHA joins ESMO in calling for EU action on shortages of essential medicines
EHA joins ESMO in calling for EU action on shortages of essential medicines
The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…
EHA-HKSH Hematology Tutorial
EHA is joining the Hong Kong Society of Hematology (HKSH) to organize the EHA-HKSH Hematology Tutorial on Lymphoid Malignancies.
Read moreEHA-SWG on AAA a virtual meeting with a worldwide approach covering all aspects of the disease!
Live days: April 29-30, 2021
Content available: April 22, 2021 – May 29, 2021
Chair: Prof Dr C Dufour
Junior and senior hematologists from all over the world gathered on April 29-30, 2021 for the live days of the EHA-SWG Scientific Meeting on…
SWG Educational Activities
EHA2023 Hybrid CongressDate and locationJune 8–11, 2023, in Frankfurt, Germany. ChairMarie Jose Kersten
Case discussions
Follicular Lymphoma: Martin Dreylng, Daphne De Jong. Double hit Lymphoma: Andrew Davies, Elias Campo. T-follicular helper cell lymphoma: Andrew Davies, Daphne De Jong.
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
Turning thoughts into reality
Turning thoughts into reality
By Dr Adi Zoref (@ZorefAdi)
I am an Israeli physician, trained in internal medicine. During my residency rotation in hematology at Meir Medical Center, I met a patient who changed my life.
Clinical trials
The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- »